Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss biotech Actelion expects to submit its next-generation PAH therapy macitentan for approval in the fourth quarter of this year, giving it time to replace current top-selling product Tracleer before that product loses patent protection in 2015.